Page 5 - Pharma

Analgesics, other common drugs used during Covid-19 clock double-digit CAGR

Pain and fever drug Paracetamol and blood-clot preventing Enoxaparin both post growth rates beyond 20%

PAG invests Rs 2,000 crore in Optimus Drugs for controlling stake

Exact stake size not revealed, sources put the number at 70%

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe

Indian drug firms get a shot in the arm in $12-bn Australian drug market

India has over 750 USFDA approved plants and over 4000 products which are approved by either the US or EU or any other stringent regulator.

BS Awards for Corporate Excellence 2021: Samina Hamied lauds team effort

Cipla, which has seen a generational change in its leadership, draws 40 per cent of its revenues from India and 21 per cent from the US market.

MedisimVR raises Rs 3.5cr in pre-series A round led by IP Ventures

The funds raised by MedisimVR will be used by the company for scaling up its product offering and adding more skill training content to their library

Zydus unit to acquire brand from US-based BridgeBio Pharma

The agreement further adds to company's portfolio of medicines for rare and orphan diseases

Booster dose: India's pharma sector to grow at 6-8% YoY in FY23

India Ratings and Research (Ind-Ra) said it has maintained a neutral outlook for the Indian pharmaceutical sector for FY23.

Valuations turning attractive for Dr Reddy's as company outperforms sector

US price erosion, India growth trends would be keenly tracked

PM Modi calls upon private firms to enter medical sector in big way

His remarks assume significance at a time when a large number of Indian students, many of them studying medicine, have been stuck in Ukraine following the Russian attack on that country.

Online healthcare firm MediBuddy raises $125 mn in Series-C funding

MediBuddy, which recently got actor Amitabh Bachchan as a brand ambassador, is aiming to scale up business

Jubilant Pharma: Fitch revises outlook to 'negative'; affirms 'BB' rating

Fitch estimates the pharma company's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11%

President Biden puts focus on drug prices as he tries to revive agenda

Efforts to lower prescription drug costs have long been popular with voters, but bipartisan consensus has proved elusive. It's unclear if there's a political path forward for Biden's plans in Congress

Bugworks Research gets $18mn funding as it scales up clinical research

The Series B1 financing was led by Lightrock India

What are Lupin CEO Vinita Gupta's plans for growth in US & China?

In conversation with Business Standard's Sohini Das, Lupin CEO Vinita Gupta shared her company's growth plans in the US and in China. Let us listen in to the interview

Fewer launches subdue pharma market's Dec sequential growth

As per India Ratings and Research (Ind-Ra), IPM continued to deliver slower growth of 5.3 per cent YoY in December 2021 after growing 6.6 per cent in November 2021

Emcure Pharma's Rs 5,000-crore IPO to hit market early next month

Emcure Pharmaceuticals has received regulatory approvals for its draft red herring prospectus and will shortly be filing the RHP for the Rs 5,000-crore initial share sale, which will hit the market soon after the Budget, according to merchant banking sources. The IPO consists of a fresh issue of up to Rs 1,100 crore by the company, which will be used as growth capital, and an offer for sale by promoter shareholders -- founder, managing director & chief executive Satish Mehta who owns 41.92 per cent and by son Sunil Mehta who holds 6.13 per cent. Other promoter groups/persons who are participating in the OFS collectively own 33.55 per cent, and global private equity major Bain Capital owns 13.09 per cent in the Pune-headquartered pharma major which is the 12th largest player in the country. The sources, however, did not disclose how much each of the selling promoters will be offloading through the OFS. The company will utilize Rs 947 crore from the proceeds of the issue to ...

Granules India gets USFDA nod for its generic Amphetamine mixed salts

This is for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy

Pharma players to launch anti-Covid pill shortly after DCGI approval

Homegrown pharma majors Sun Pharma, Cipla, Hetero, Torrent announced plans to market their versions of antiviral drug Molnupiravir to treat high-risk adult patients with Covid across India shortly.

Trials start for Equillium drug for autoimmune disease after India approval

Equillium secured exclusive rights to develop and commercialise itolizumab for the US and Canada markets, in May 2017.